653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma


Jacob P. Laubach, Jonathan L. Kaufman, Douglas W. Sborov, et al.

The addition of DARA resulted in RVd induction and consolidation associated with ASCT after two years of maintenance therapy, followed by DARA plus R maintenance. Deep and sustained responses were also observed in patients with transplantable NDMM, including sCR and MRD negativity (10-5 and 10-6) rates. There were no new security concerns. These data support the use of D-RVd induction / consolidation and D-R maintenance in transplant eligible NDMM patients.



Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, et al.

Intermediate fit patients benefit from the effective and feasible therapy combination ixazomib, daratumumab and dexamethasone, which improves their quality of life. However, discontinuation of treatment due to toxicity gives cause for concern: the entire treatment regimen is six percent, but especially only of ixazomib with eleven percent, or an incompliance that negatively affects progression-free survival.



Gordon Cook, Charlotte Pawlyn, Kara-Louise Royle, et al.

The study shows that the recruitment of older, less fitter patients for clinical trials is feasible. For more information see abstract.


Magaret Macro, Cyrille Touzeau, Clara Mariette, et al.

Ixazomib and daratumumab without dexamethasone have a favorable safety profile in this population of very elderly frail patients with RRMM. Almost a third of them had high-risk cytogenetic therapy.



Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.

The addition of venetoclax to bortezomib and dexamethasone resulted in significantly improved progression-free survival, but increased mortality compared to Pbo in the general population. As in previous studies, venetoclax, in addition to bortezomib and dexamethasone, had the greatest improvement in progression-free survival in patients with t (11; 14) or high BCL2 with a favorable benefit-risk profile.



Herve Avet Loiseau, Pieter Sonneveld, Philippe Moreau, et al.

In the CASSIOPEIA study, D-VTd ind / ASCT / cons and daratumumab maintenance therapy showed the highest and most sustained MRD negativity rates. A reduced intensity (Q8W) of DARA maintenance therapy did not significantly improve MRD negativity compared to observation in patients treated with D-VTd. Although not long-lasting, daratumumab maintenance improved MRD negativity in patients treated with VTd.